Previously, therapeutic use of the MDM2-p53 inhibitor APG-115 obtained FDA orphan drug designation for the treatment of gastric cancer 41, SD49-7, which triggers MDM2 inhibition via KDM4s, represents a promising candidate for developing new targeted drugs in leukemia treatment. Here, TP53 is linked to leukemia.